FINWIRES · TerminalLIVE
FINWIRES
Novo Nordisk

Novo Nordisk

$NVO
NYSEPharmaceuticals

93 stories mentioning Novo NordiskUpdated 5d ago

A drugmaker in focus as CMS proposed a permanent Medicare drug-price-negotiation framework from 2029, while healthcare stocks rose.

Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.7%.The iShares Biotechnology ETF (IBB) decreased 0.3%.In corporate news, Tenet Healthcare (THC) shares surged past 17% after it posted higher Q2 adjusted earnings and revenue, and raised its 2026 guidance.Novo Nordisk (NVO) is seeking a preliminary US court injunction to immediately block advertising by Eli Lilly (LLY) for its obesity and diabetes drugs, escalating the companies' legal dispute over weight-loss drug marketing, Reuters reported Friday. Novo shares rose 1.9%, and Lilly was up 0.6%.Profound Medical (PROF) said new data from a Level 1 evidence trial of its MRI-guided Tulsa procedure demonstrated statistically significant superiority over robotic radical prostatectomy in men with intermediate-risk prostate cancer. Its shares jumped past 8%.Lisata Therapeutics (LSTA) shares fell 16% after the company said it has terminated its planned merger with Kuva Labs.

$LLY$LSTA$NVO$PROF$THC
Sectors

Sector Update: Healthcare Stocks Rise in Afternoon Trading

Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding about 0.8%.The iShares Biotechnology ETF (IBB) increased 0.2%.In corporate news, Novo Nordisk (NVO) is seeking a preliminary US court injunction to immediately block advertising by Eli Lilly (LLY) for its obesity and diabetes drugs, escalating the companies' legal dispute over weight-loss drug marketing, Reuters reported Friday. Novo shares rose 1.7%, and Lilly was up 1.3%.Tenet Healthcare (THC) shares jumped past 17% after it posted higher Q2 adjusted earnings and revenue, and raised its 2026 guidance.Scribe Therapeutics (SCTX) shares surged 50% in their Friday debut on Nasdaq after the company priced its IPO of 8.58 million shares at $15 per share.

$LLY$NVO$SCTX$THC
Sectors

Sector Update: Healthcare

Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding about 0.8%.The iShares Biotechnology ETF (IBB) increased 0.2%.In corporate news, Novo Nordisk (NVO) is seeking a preliminary US court injunction to immediately block advertising by Eli Lilly (LLY) for its obesity and diabetes drugs, escalating the companies' legal dispute over weight-loss drug marketing, Reuters reported Friday. Novo shares rose 1.6%, and Lilly was up 1.2%.

$LLY$NVO
Wire

Update: Market Chatter: Novo Nordisk Seeks Immediate Court Order Against Lilly's Weight-Loss Drug Ads

(Updates with responses from Novo Nordisk and Eli Lilly in the fourth and fifth paragraphs.)Novo Nordisk (NVO) is seeking a preliminary US court injunction to immediately block advertising by Eli Lilly (LLY) for its obesity and diabetes drugs, escalating the companies' legal dispute over weight-loss drug marketing, Reuters reported Friday.According to the report, Novo Nordisk said it filed the request after suing Lilly earlier this week, alleging false advertising and unfair competition related to marketing campaigns for Zepbound and Mounjaro.Novo alleges Lilly's ads misrepresented how the companies' drugs compare. Lilly denied the allegations and said it will vigorously defend the lawsuit, Reuters added.In a statement emailed to, John Kuckelman, Senior Vice President and Group General Counsel, Novo Nordisk, said: "Millions of Americans living with obesity and type 2 diabetes rely on these medicines. Misleading advertisements that selectively compare lower doses of Novo Nordisk's medicines against higher doses of Lilly's medicines, based on outdated studies, leave patients with the mistaken impression that Lilly's drugs are vastly superior, and that is simply not true."A Lilly spokesperson commented: "Head-to-head clinical trials are the strongest evidence for comparing medicines. SURMOUNT-5 and SURPASS-2 are the only head-to-head, randomized clinical trials directly comparing tirzepatide and semaglutide - and Novo Nordisk wants to stop Lilly from sharing their results. Novo Nordisk has never tested its highest doses of semaglutide against Lilly's tirzepatide medicines in any clinical trial; instead, it is using a lawsuit to advance comparisons it has never put to the test. We stand behind the science and our advertising, and we will oppose this motion vigorously."(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $48.98, Change: $+0.80, Percent Change: +1.65%

$LLY$NVO
Asia Markets

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading

European equities traded in the US as American depositary receipts were tracking higher late Friday morning, rising 0.55% to 1,910.34 on the S&P Europe Select ADR Index, which is up about 0.4% for the week so far.From continental Europe, the gainers were led by software firm SAP (SAP) and semiconductor company Sequans Communications (SQNS), which rose 7% and 2.8%, respectively. They were followed by pharmaceutical firm Novo Nordisk (NVO) and lender Banco Santander (SAN), which advanced 2.5% and 2.4%, respectively.The decliners from continental Europe were led by telecommunications company Nokia (NOK) and biopharmaceutical company DBV Technologies (DBVT), which dropped 4.7% and 2.9% respectively. They were followed by internet ad firm Criteo (CRTO) and biotech company BioNTech (BNTX), which lost 2.1% and 1.3% respectively.The gainers from the UK were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and communications company WPP (WPP), which increased 3.7% and 2.3% respectively. They were followed by medical device maker Smith & Nephew (SNN) and educational publisher Pearson (PSO), which were up 1.7% and 1.6% respectively.The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Bicycle Therapeutics (BCYC), which fell 4.7% and 3% respectively. They were followed by biopharmaceutical company Akari Therapeutics (AKTX) and biotech firm Autolus Therapeutics (AUTL), which were down 2.5% and 2% respectively.

$AKTX$AUTL$BCYC$BNTX$CRTO$DBVT$NOK$NVO$PSO$SAN$SAP$SLN$SNN$SQNS$WPP
Commodities

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid New US Tariffs

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2%, and the actively traded Invesco QQQ Trust (QQQ) advanced 0.1% in Friday's premarket activity, as investors digest new US tariffs amid continued corporate earnings.US stock futures were higher, with S&P 500 Index futures up 0.2%, Dow Jones Industrial Average futures gaining 0.4%, and Nasdaq futures advancing 0.1% before the start of regular trading.S&P Global US Manufacturing, Service, and Composite PMI are expected at 9:45 AM ET. New Home Sales are due at 10 AM ET, followed by Kansas City Fed Services at 11 AM ET.In premarket action, bitcoin was up by 0.01%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.1% higher, Ether ETF (EETH) advanced 0.2%, and Bitcoin & Ether Market Cap Weight ETF (BETH) rose over 2.6%.Power Play:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced 0.1%, the iShares US Technology ETF (IYW) was 0.6% higher, and the iShares Expanded Tech Sector ETF (IGM) was up 0.1%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) gained 0.9%, while the iShares Semiconductor ETF (SOXX) fell by 0.5%.Intel (INTC) shares were up more than 3% in premarket activity after the company reported that it swung to fiscal Q2 adjusted earnings as revenue increased during the period.Winners and Losers:EnergyThe iShares US Energy ETF (IYE) was down 0.8%, while the State Street Energy Select Sector SPDR ETF (XLE) retreated by 0.4%.SLB N.V. (SLB) stock was up more than 3% before market open after the company reported Q2 adjusted earnings Friday of $0.55 per diluted share, above analyst estimates of $0.51.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.3%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) rose 2.2%, and the iShares US Consumer Staples ETF (IYK) was inactive. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) gained 0.3%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was up 0.9%.Fly-E Group (FLYE) shares were up 2.4% pre-bell after the company said late Thursday it filed its overdue Form 10-K and expects it will eliminate the need to submit a formal plan to regain compliance with Nasdaq.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.4%, the Vanguard Industrials Index Fund (VIS) was up 0.6% and the iShares US Industrials ETF (IYJ) was inactive.C.H. Robinson Worldwide (CHRW) stock was down more than 2% before the opening bell after the company said that a Dallas County, Texas jury issued a $604 million advisory verdict against the company and two other defendants in a lawsuit stemming from a trucking accident.Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.3%, the Vanguard Health Care Index Fund (VHT) was inactive, while the iShares US Healthcare ETF (IYH) slipped 1.4%. The iShares Biotechnology ETF (IBB) was inactive.Novo Nordisk (NVO) stock was up more than 1% premarket after the company filed a preliminary US court injunction to immediately block advertising by Eli Lilly (LLY) for its obesity and diabetes drugs.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.3%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.9%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 1% lower.HSBC (HSBC) shares traded up 1% in early hours activity after the company signed the share purchase deal to sell HSBC Life in Singapore for $2.09 billion to Allianz Asia.CommoditiesFront-month US West Texas Intermediate crude oil retreated by 3.3% to $89.15 per barrel on the New York Mercantile Exchange. Natural gas was up by 1% to $2.95 per 1 million British Thermal Units. The United States Oil Fund (USO) was down 2.4%, while the United States Natural Gas Fund (UNG) was 2% higher.Gold futures for July advanced 0.2% to $4,057.90 an ounce on the Comex. Silver futures were up 1.1% to $58.71 an ounce. SPDR Gold Shares (GLD) increased 0.1%, and the iShares Silver Trust (SLV) was 1.4% higher.

Dow JonesNasdaq CompositeS&P 500$BETH$BITO$CHRW$EEM$EETH$EXI$FAS$FAZ$FLYE$GLD$HSBC$IBB$IGM$IGV$INTC$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$NVO$PMR$QQQ$RTH$SLB$SLV$SOXX$SPY$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Sectors

Sector Update: Healthcare Stocks Rise Late Afternoon

Healthcare stocks advanced late Tuesday afternoon with the NYSE Healthcare Index rising 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.4%.The iShares Biotechnology ETF (IBB) climbed 1.3%.In corporate news, Novo Nordisk (NVO) sued rival Eli Lilly (LLY) in the US over alleged "misleading" advertising campaigns for its obesity and diabetes drugs that compete with the Danish drugmaker's products. Novo shares fell 0.7%, and Lilly rose 1.7%.Danaher (DHR) raised its full-year profit guidance as fiscal Q2 results came in stronger than expected. The company lowered the top end of its 2026 revenue growth outlook, and the shares fell 11%.Okyo Pharma (OKYO) shares rose 5.8%. Chairman Gabriele Cerrone increased his stake in the company to 10.9 million shares, or 20.5% of the issued shares, with the purchase of 25,000 shares at $1.40 each.MapLight Therapeutics (MPLT) is seen having meaningful upside in the ML-007 Phas2 2 schizophrenia trial readout with data expected in mid-August, UBS Securities said. MapLight shares rose 4.1%.

$DHR$LLY$MPLT$NVO$OKYO
Sectors

Sector Update: Healthcare Stocks Advance Tuesday Afternoon

Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.1%.The iShares Biotechnology ETF (IBB) gained 1%.In corporate news, Novo Nordisk (NVO) on Tuesday sued rival Eli Lilly (LLY) in the US over alleged "misleading" advertising campaigns for its obesity and diabetes drugs that compete with the Danish drugmaker's products. Novo shares were down 0.6%, and Lilly was rising 1.2%.Danaher (DHR) raised its full-year profit guidance on Tuesday as its fiscal Q2 results came in stronger than expected, but the company lowered the top end of its 2026 revenue growth outlook. Its shares fell past 12%.Okyo Pharma (OKYO) shares jumped past 8% after it said Chairman Gabriele Cerrone has increased his stake in the company to 10.9 million shares, or 20.5% of the company's issued share capital, with the purchase of 25,000 ordinary shares at $1.40 per share.

$DHR$LLY$NVO$OKYO
Sectors

Sector Update: Healthcare

Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.2%.The iShares Biotechnology ETF (IBB) climbed up 1%.In corporate news, Novo Nordisk (NVO) on Tuesday sued rival Eli Lilly (LLY) in the US over alleged "misleading" advertising campaigns for its obesity and diabetes drugs that compete with the Danish drugmaker's products. Novo shares were down 0.6%, and Lilly was rising 1.1%.

$LLY$NVO
Novo Nordisk Sues Eli Lilly Over Alleged 'Misleading' Ad Campaigns
US Markets

Novo Nordisk Sues Eli Lilly Over Alleged 'Misleading' Ad Campaigns

Novo Nordisk (NVO) on Tuesday sued rival Eli Lilly (LLY) in the US over alleged "misleading" advertising campaigns for its obesity and diabetes drugs that compete with the Danish pharmaceutical giant's products.The lawsuit, filed in the US District Court for the District of New Jersey, accused Lilly of being in "multiple violations of federal and state false advertising and unfair competition laws," Novo said in a statement.Lilly's ad campaigns in the US for its weight-loss drug Zepbound and Mounjaro diabetes treatment are based on what Novo described as "outdated studies" comparing highest doses of Lilly's drugs versus lower doses of Novo's Wegovy and Ozempic brands."These high-profile US advertising campaigns create the misleading impression that Lilly's medicines are superior, including by withholding critical scientific evidence about newer, more effective (US Food and Drug Administration-approved) options," Novo said.The Danish drugmaker is seeking a permanent injunction to stop the advertising across all platforms and require Lilly to run corrective ads."We have also communicated to Lilly that if they do not voluntarily pull these ads, Novo Nordisk intends to file a formal motion with the court in the coming days seeking a preliminary injunction to immediately block them, with evidence that consumers are being confused and misled by Lilly's ads," Novo said.Lilly disputed the allegations and said it intends to fight the lawsuit."The gold standard for comparing medicines is a robustly designed, well-conducted head-to-head clinical trial -- like SURMOUNT-5, which remains the only head-to-head, randomized clinical trial directly comparing tirzepatide and semaglutide in weight management," a Lilly spokesperson said in a statement e-mailed to."Rather than compete on the merits of its products, Novo is asking a court to stop Lilly from communicating the results of that trial," the spokesperson said. "We stand firmly behind our advertising."Lilly shares were up 1.4% in Tuesday afternoon trade, while Novo's New York Stock Exchange-traded American depositary receipts were down 0.4%.Price: $49.41, Change: $-0.20, Percent Change: -0.40%

$LLY$NVO
Wire

Update: Novo Nordisk Sues Eli Lilly Over Zepbound, Mounjaro Advertising

(Updates with Eli Lilly's response in the fifth and sixth paragraphs.)Novo Nordisk (NVO) said Tuesday it filed a lawsuit against Eli Lilly (LLY) in US District Court for the District of New Jersey, alleging the drugmaker's advertising for Zepbound and Mounjaro violates federal and state false advertising and unfair competition laws.Novo Nordisk said Lilly's ads compare Zepbound and Mounjaro with lower doses of Wegovy and Ozempic while omitting information about higher-dose versions of the semaglutide drugs, making the ads misleading.The company said it is seeking a permanent injunction to stop the advertising and require Lilly to run corrective ads.Novo Nordisk added it plans to seek a preliminary injunction after Lilly declined to remove or revise the campaigns following a cease-and-desist request.An Eli Lilly spokesperson toldin an emailed response that rather than competing on the merits of its products, Novo is urging the court to stop it from communicating trial results, and it will defend against the lawsuit vigorously."We stand firmly behind our advertising. It is truthful, it is transparent, and it is grounded in the most direct scientific evidence available - exactly what patients deserve," the spokesperson added.Price: $49.38, Change: $-0.23, Percent Change: -0.46%

$LLY$NVO
Wire

Top Midday Stories: 3M Shares Rise on Strong Guidance; Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising

All three major US stock indexes were up in late-morning trading Tuesday, as investors focused on some strong corporate earnings reports.In company news, 3M (MMM) reported Q2 adjusted earnings Tuesday of $2.40 per share, up from $2.16 a year earlier and above the FactSet consensus analyst estimate of $2.25. Second-quarter revenue was $6.5 billion, up from $6.34 billion a year ago and above the FactSet consensus of $6.40 billion. For fiscal 2026, the company expects adjusted EPS of $$8.80 to $8.95, up from its previous outlook of $8.50 to $8.70 and above the FactSet consensus of $8.74. 3M shares were up 8.7% around midday.Novo Nordisk (NVO) said Tuesday it filed a lawsuit against Eli Lilly (LLY) in the US District Court for the District of New Jersey alleging the drugmaker's advertising for Zepbound and Mounjaro violates federal and state false advertising and unfair competition laws. Novo shares were down 0.3%, while Lilly shares were up 1.3%.Utz Brands (UTZ) has entered into a definitive agreement through which Intersnack Group will acquire all of its outstanding common stock for $14.25 per share in cash and take it private, the companies said Tuesday. The price represents an enterprise value of about $2.9 billion and a 91% premium over Utz's closing price on July 20, the companies said. The deal is expected to close in Q4, subject to regulatory and other conditions, they said. Utz shares were up 89.5%.Danaher (DHR) reported Q2 adjusted net earnings Tuesday of $1.94 per diluted share, up from $1.80 a year earlier and above the FactSet consensus of $1.84. Second-quarter sales were $6.27 billion, up from $5.94 billion a year ago and above the FactSet consensus of $6.11 billion. For full-year 2026, the company raised its adjusted diluted EPS guidance to $8.45 to $8.60 from $8.35 to $8.55. Analysts polled by FactSet expect $8.45. Danaher shares were down $14.1%.General Motors (GM) reported Q2 adjusted diluted EPS Tuesday of $3.57, up from $2.53 a year earlier and above the FactSet consensus of $3.19. Second-quarter revenue was $48.03 billion, up from $47.12 billion a year ago and above the FactSet consensus of $47.01 billion. For 2026, the company expects adjusted EPS of $12 to $14, compared with the FactSet consensus of $12.97. GM shares were up 4.0%.MSCI (MSCI) reported Q2 adjusted EPS of $4.94, up from $4.17 a year earlier but below the FactSet consensus of $4.99. Second-quarter operating revenue was $867 million, up from $772.7 million a year ago but below the FactSet consensus of $870.7 million. MSCI shares were down 8.7%.Price: $49.45, Change: $-0.16, Percent Change: -0.33%

$DHR$GM$LLY$MMM$MSCI$NVO$UTZ
Asia Markets

European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday

European equities traded in the US as American depositary receipts were slightly lower on Thursday morning, down 0.07% to 1,911.26 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by pharmaceutical company Novo Nordisk (NVO) and drink and brewing company Anheuser-Busch Inbev (BUD), which rose 1.9% and 0.9% respectivelyThey were followed by pharmaceutical company Novartis (NVS), which added 0.8%.The decliners from continental Europe were led by tech companies Nokia (NOK) and Ericsson (ERIC), which fell 7.8% and 1.8% respectively.They were followed by bank Santander (SAN), which shed 1.5%.From the UK and Ireland, the gainers were led by advertising and PR agency WPP (WPP) and telecom giant Vodafone (VOD), which rose 3.8% and 3% respectively. They were followed by beverage company Diageo (DEO), which added 2.5%.The decliners from the UK and Ireland were led by semiconductor company Arm (ARM) and pharmaceutical company Compass Pathways (CMPS), which lost 6.9% and 2.1% respectively.

$ARM$BUD$CMPS$DEO$ERIC$NOK$NVO$NVS$SAN$VOD$WPP
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.1%.The iShares Biotechnology ETF (IBB) added 0.5%.In corporate news, Novo Nordisk (NVO) shares gained 2.9% after it said Wednesday the European Commission granted marketing authorization for its Wegovy pill for the treatment of adults with obesity or overweight with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.Elevance Health (ELV) reported sequential and annual declines in its Q2 memberships, although the health insurer lifted its full-year earnings outlook and recorded an unexpected year-over-year revenue increase in the previous three-month period. The shares fell past 9%.Veradermics (MANE) shares jumped 12% after the company said its VDPHL01 achieved rapid onset of hair growth with the majority of participants in a phase 2 clinical trial of females with mild-to-moderate pattern hair loss.Eli Lilly-backed (LLY) AdvanCell has raised $315 million from its Series D financing, with participating investors such as Bain Capital and Fidelity Management & Research, Bloomberg reported. Lilly shares were fractionally higher.

$ELV$LLY$MANE$NVO
Sectors

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.3%.The iShares Biotechnology ETF (IBB) added 0.3%.In corporate news, Novo Nordisk (NVO) shares rose 2.5% after it said Wednesday the European Commission granted marketing authorization for its Wegovy pill for the treatment of adults with obesity or overweight with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.Elevance Health (ELV) reported sequential and annual declines in its Q2 memberships, although the health insurer lifted its full-year earnings outlook and recorded an unexpected year-over-year revenue increase in the previous three-month period. The shares fell past 8%.Johnson & Johnson (JNJ) raised its full-year outlook on Wednesday after reporting better-than-expected Q2 results, driven by growth in its innovative medicine and medical device businesses. Its shares were still down 1.7%.Eli Lilly-backed (LLY) AdvanCell has raised $315 million from its Series D financing, with participating investors such as Bain Capital and Fidelity Management & Research, Bloomberg reported. Lilly shares shed 0.4%.

$ELV$JNJ$LLY$NVO
Sectors

Sector Update: Healthcare

Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.3%.The iShares Biotechnology ETF (IBB) added 0.3%.In corporate news, Novo Nordisk (NVO) shares rose 2.6% after it said Wednesday the European Commission granted marketing authorization for its Wegovy pill for the treatment of adults with obesity or overweight with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.

$NVO
Wire

Novo Nordisk Gets EU Approval for Wegovy Pill for Weight Management

Novo Nordisk (NVO) said Wednesday the European Commission granted marketing authorization for Wegovy pill for the treatment of adults with obesity or overweight with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.The approval makes Wegovy pill the first GLP-1 receptor agonist available in tablet form for weight management in the European Union. The company said the authorization is the fifth for Wegovy pill after approvals in the US, UK, UAE and Bahrain.The approval was based on the Oasis clinical trial program, including the phase 3b Oasis 4 trial. In that trial, once-daily oral semaglutide 25 mg demonstrated about 17% weight loss compared with 3% for placebo when used alongside lifestyle intervention.The European Commission also approved Wegovy 7.2 mg injection in a single-dose pen for people living with obesity. Novo Nordisk said it plans to launch Wegovy pill in additional countries in H2.Price: $50.59, Change: $+1.52, Percent Change: +3.09%

$NVO
Asia Markets

European Equities Traded in the US as American Depositary Receipts Advance Wednesday

European equities traded in the US as American depositary receipts were rising on Wednesday morning, increasing 0.7% to 1,905.92 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by budget airline Ryanair (RYAAY) and health technology company Philips (PHG), which rose 3.9% and 3.8% respectively. They were followed by pharmaceutical giant Novo Nordisk (NVO) and healthcare firm Grifols (GRFS), which added 2.9% and 2.4%.The decliners from continental Europe were led by technology company Nokia (NOK) and bank BBVA (BBVA), which fell 4.7% and 1.1% respectively.From the UK and Ireland, the gainers were led by medical laboratory company Trinity Biotech (TRIB) and advertising and PR agency WPP (WPP), which rose 5.9% and 3.1% respectively. They were followed by hospitality group InterContinental Hotels (IHG), which added 1.1%.The decliners from the UK and Ireland were led by telecom giant Vodafone (VOD), which shed 2.5%, and mining company Rio Tinto (RIO), which decreased 0.6%.

$BBVA$GRFS$IHG$NOK$NVO$PHG$RIO$RYAAY$TRIB$VOD$WPP
Microsoft Invests $2.5 Billion in New AI Implementation Business
US Markets

Microsoft Invests $2.5 Billion in New AI Implementation Business

Microsoft (MSFT) is launching a new business unit with a $2.5 billion investment that will help clients with artificial intelligence implementations, the technology giant said Thursday.The new business will be called Microsoft Frontier Co. and embed 6,000 experts at customers across the globe to help co-design, deploy and improve AI systems at scale. Rodrigo Kede Lima is expected to lead the unit as president.Microsoft Frontier helps focus on "end-to-end frontier transformation, enabling customers to amplify their IQ with AI while refining their differentiated value in the markets that they serve," Judson Althoff, chief executive of Microsoft Commercial Business, said in a blog post.On Tuesday, Amazon.com's (AMZN) cloud-computing unit, Amazon Web Services, said it's investing $1 billion in a new unit called AWS Forward Deployed Engineering that is focused on helping customers co-develop and deploy agentic AI tools in a matter of days."This goes beyond what has been labeled as Forward Deployed Engineering (FDE) and will be the largest, most capable, outcome-driven engineering organization in the industry," Althoff said Thursday.Microsoft shares were up 1.9% in late-afternoon trade. So far this year, the stock has lost 19% in value.The company is already working with global clients, including London Stock Exchange Group, Unilever (UL), and Novo Nordisk (NVO). Microsoft said it has FDE partnerships with Accenture (ACN), EY, KPMG, PwC and others.Price: $391.38, Change: $+7.10, Percent Change: +1.85%

$ACN$AMZN$MSFT$NVO$UL
Asia Markets

European Equities Traded in the US as American Depositary Receipts Fall Sharply in Wednesday Trading

European equities traded in the US as American depositary receipts were tracking sharply lower late Wednesday morning, falling 1.61% to 1,890.71 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by internet advertising firm Criteo (CRTO) and biotech company Evaxion (EVAX), which rose 3% and 2.9% respectively. They were followed by pharmaceutical company Novo Nordisk (NVO) and software firm SAP (SAP), which were up 2.6% and 2.4% respectively.The decliners from continental Europe were led by telecommunications company Ericsson (ERIC) and pharmaceutical company Sanofi (SNY), which lost 2.6% and 2.3% respectively. They were followed by oil and gas company Eni (E) and brewing company Anheuser-Busch InBev (BUD), which fell 2.2% and 1.3% respectively.The gainers from the UK were led by software firm Endava (DAVA) and biopharmaceutical company NuCana (NCNA), which advanced 5.7% and 3.3% respectively. They were followed by insurance company Prudential (PUK) and educational publisher Pearson (PSO), which increased 2.6% and 2.1% respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and biotech firm Trinity Biotech (TRIB), which fell 9.4% and 6.8% respectively. They were followed by pharmaceutical company AstraZeneca (AZN) and hospitality company InterContinental Hotels Group (IHG), which decreased 3% and 2.7% respectively.

$AZN$BDRX$BUD$CRTO$DAVA$E$ERIC$EVAX$IHG$NCNA$NVO$PSO$PUK$SAP$SNY$TRIB

Showing 1-20 of 93

Track with the FINWIRES app suite

FolioX
FolioX
Track Novo Nordisk in your portfolio
WheelAI
WheelAI
Analyze Novo Nordisk options with the wheel strategy
StockInsider
StockInsider
See market sentiment on Novo Nordisk